- Home
- TNGX vs NVAX Comparison
TNGX vs NVAX Comparison
Compare TNGX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | NVAX |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TNGX | NVAX |
|---|---|---|
| Price | $16.29 | $10.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $17.50 | $11.33 |
| AVG Volume (30 Days) | 3.5M | ★ 4.3M |
| Earning Date | 06-01-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.89 | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | $62,384,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.81 | N/A |
| P/E Ratio | ★ N/A | $3.85 |
| Revenue Growth | 48.29 | ★ 64.69 |
| 52 Week Low | $1.04 | $5.01 |
| 52 Week High | $17.63 | $11.85 |
Technical Indicators
Market Signals| Indicator | TNGX | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 69.95 | 58.95 |
| Support Level | $10.90 | $6.34 |
| Resistance Level | N/A | $10.42 |
| Average True Range (ATR) | 1.16 | 0.71 |
| MACD | 0.44 | 0.02 |
| Stochastic Oscillator | 79.65 | 49.70 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.